You are browsing articles on the topic of Heart Failure Archives - CardioExchange

Avatar of Vinay

Let’s Take a Close Look at PARADIGM-HF (1 Sep 2014)

Voices

Vinay Prasad, MD MPH

Vinay Prasad explores three reasons why clinicians should have reservations about the findings from PARADIGM-HF.

Avatar of Larry Husten, PHD

SIGNIFY Trial Provokes Sound and Fury Over Controversial Drug (31 Aug 2014)

News

The already controversial drug ivabradine just got a little more controversial. The drug, which is marketed by Servier under the brand names of Corlentor and Procoralan, is available in Europe and elsewhere and is used for the treatment of heart failure and stable angina. The drug is not available in the U.S., but it is under development by Amgen for a…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of John McMurray, MbChB MD

Will There Be a PARADIGM Shift in Treatment of Heart Failure? (30 Aug 2014)

Voices

John McMurray, MbChB MD and Milton Packer, MD

John J.V. McMurray and Milton Packer, the two lead authors of the PARADIGM-HF trial, discuss the randomized comparison of angiotensin–neprilysin inhibition with the ACE inhibitor enalapril.

Avatar of Larry Husten, PHD

Predicting PARADIGM-HF, or What to Expect When You’re Expecting (28 Aug 2014)

Voices

Larry Husten, PhD

Larry Husten analyzes the expectations surrounding the upcoming release of PARADIGM-HF and its centerpiece LCZ696 from the perspective of the medical field as well as the world of economics.

Avatar of John

The CardioMEMS HF System: What Do You Say to Your Patient? (14 Aug 2014)

Voices

John Ryan, MD

In this scenario based on a patient’s question about the CardioMEMS device, John Ryan asks, “What do you say to your patient?”

Avatar of Larry Husten, PHD

Study Offers Little Support for an Old Drug (11 Aug 2014)

News

Digoxin is one of the oldest drugs in the cardiovascular arsenal, derived from the foxglove plant and first described in the 18th century by William Withering. It is frequently used in patients with heart failure (HF) and with atrial fibrillation (AF). The few trials supporting its use were performed in HF patients before newer treatments…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Ileana

Cardiac Rehab for Heart Failure Patients: The CMS Is Convinced — Are You? (29 Jul 2014)

Voices

Ileana Piña, MD, MPH and John Ryan, MD

John Ryan interviews Dr. Ileana Piña about her work in HF-ACTION as it relates to the CMS’s recent expansion of cardiac rehabilitation coverage.

Avatar of Colleen

Behind the Patient Decision-Making Process for a Destination-Therapy LVAD (10 Jul 2014)

Voices

Colleen Kelley McIlvennan, DNP, ANP, Larry Allen, MD, MHS, and Dan Matlock, MD, MPH

Colleen K. McIlvennan, Larry A. Allen, and Daniel D. Matlock discuss their study of how patients choose whether to get a left ventricular assist device as destination therapy.

Avatar of Larry Husten, PHD

Sitagliptin Associated with Increase in Heart Failure Hospitalizations (3 Jul 2014)

News

The cardiovascular effects of drugs used for glucose control in patients with diabetes have been a subject of controversy for many years now. More recently, attention has started to focus specifically on the risk for heart failure (HF). Now, an observational study will likely raise new questions about the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin (Januvia, Merck)….

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Positive Results for New Oral Pulmonary Arterial Hypertension Drug (16 Jun 2014)

News

Actelion has announced positive top-line results for a phase III trial of a new oral drug for the treatment of pulmonary arterial hypertension (PAH). The drug, selexipag, is a first-in-class orally available selective prostacyclin IP receptor agonist. The pivotal, double-blind GRIPHON study was the largest outcome trial ever performed in PAH. A total of 1,156 PAH patients were randomized to selexipag or…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.